Spinal Muscular Atrophy (SMA) - Epidemiology Forecast to 2027

  • ID: 4520728
  • Report
  • 60 pages
  • DelveInsight
UP TO OFF
until Dec 31st 2018
1 of 3
This report titled ‘Spinal Muscular Atrophy (SMA) - Epidemiology Forecast to 2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of SMA in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

Geography Covered:
  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
Study Period: 2017-2027

Spinal Muscular Atrophy (SMA) Epidemiology
The Spinal Muscular Atrophy epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for SMA are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Spinal Muscular Atrophy (SMA) Epidemiology Segmentation

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [total diagnosed prevalent cases of SMA and diagnosed prevalence SMA cases by types (SMA Type 1, Type 2, Type 3 & Type 4)] scenario in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2027.

The report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to this research, total prevalent population of Spinal Muscular Atrophy in 7 major markets is found out to be 38,900 in 2017.

Report Scope:
  • The report covers detailed overview of SMA explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The report provides the insight about the historical and forecasted patient pool of SMA in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
  • The Report assesses the disease risk and burden and highlights the unmet needs of the disease
  • The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report provides the segmentation of the disease epidemiology by types (Type 1, Type 2, Type 3 & Type 4)
Key Strengths:
  • 10 Year Forecast of SMA epidemiology
  • 7MM Coverage
  • Diagnosed Prevalent cases of SMA
  • Prevalent Cases according to segmentation: SMA by types (Type 1, Type 2, Type 3 & Type 4) in 7MM
Key Assessments:
  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. Report Summary

2. Spinal Muscular Atrophy: Background & Overview
2.1. Introduction
2.2. Classification
2.3. Causes
2.4. Pathophysiology
2.5. Symptoms
2.6. Diagnosis

3. Epidemiology and Patient Population
3.1. Population and Forecast Parameters
3.2. Key Notes
3.3. Prevalent Population of SMA in 7MM
3.4. Diagnosed Prevalent SMA Cases in 2017
3.5. Diagnosed Prevalent SMA Cases in 2027
3.6. United States
3.6.1. Diagnosed Prevalent Cases of SMA in United States
3.7. EU5 (Germany, France, UK, Spain & Italy)
3.8. Germany
3.8.1. Diagnosed Prevalent Cases of SMA in Germany
3.9. France
3.9.1. Diagnosed Prevalent Cases of SMA in France
3.10. United Kingdom
3.10.1. Diagnosed Prevalent Cases of SMA in UK
3.11. Spain
3.11.1. Diagnosed Prevalent Cases of SMA in Spain
3.12. Italy
3.12.1. Diagnosed Prevalent Cases of SMA in Italy
3.13. Japan
3.14. Diagnosed Prevalent Cases of SMA in Japan

4. Appendix

5. Report Methodology
5.1. Sources Used

6. Consulting Services

7. Disclaimer

8. About the Publisher

List of Tables
Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)

List of Figures
Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll